Project

① Product Introduction / Solution
These strains show the effective results of the composition for preventing overweight, hyperlipidemia and metabolic disease.
​They help preventing obesity by lower cholesterol, adipocyte, triglyceride, subcutaneous fat and prevent diabetes by lower insulin or glucose concentration in the blood and control insulin resistance.

② Product Advantages / Differentiators / Innovation
Patent submitted - Composition for treating obesity or diabetes mellitus comprising Lactobacillus paracasei LM1010 and Lactobacillus rhamnosus LM1019

Project Summary

Business Model

Main Achievements

Sept. 2015 Genome and Company Set up
Jan. 2016 Initial Investment from Venture Capital(DSC)
Feb. 2016 Genome and Company Research Institute set up
Oct. 2016 Korean Government Tech Incubator Program awarded
Dec. 2016 Additional Investment from Venture Capital(Korea Investment Partners, etc)
Jan. 2017 Office movement to Pankyo Innovalley
Feb. 2017 Singapore office set up through KHIDI’s MedTech center
Mar. 2017 Korea Institute of Startup & Entrepreneurship Development Chairman prize awarded
April. 2017 Company Presentation & Partnering at 4th Mircobiome Business & R&D Collaboration Forum @ Amsterdam
June 2017 Korean Government Star venture Program awarded
June 2017 Company Presentation & Partnering at BIO US @ San Diego
July 2017 KHIDI’s Promising venture support program awarded
July 2017 Business Collaboration contract with Lactomason
Sept. 2017 Business Collaboration contract with Mediogen
Nov. 2017 Company Presentation & Partnering at 5th Mircobiome Business & R&D Collaboration Forum @ San Diego
Nov. 2017 Company Presentation & Partnering at BIO Europe @ Berlin
Dec. 2017 Company Presentation & Partnering at K-Startup Summit Beijing
Jan. 2018 Business and R&D Collaboration contract with CKD Bio